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Introduction
CM is a prevalent, disabling primary headache disorder.
Most patients in CM clinical trials overuse AHM. The
efficacy of prophylactic medications in CM patients
without overuse of AHM is unclear.
Objective
To evaluate the efficacy and tolerability of onabotulinum-
toxinA in a chronic migraine (CM) subgroup without
acute headache medication (AHM) overuse (MO-No).
Design/methods
PREEMPT (two phase 3 studies: 24-week, double-blind,
placebo-controlled, parallel-group phase, followed by 32-
week, open-label phase) evaluated onabotulinumtoxinA
for prophylaxis of headaches in CM (¡Ý15 days/month
with headache lasting ¡Ý4 hours/day). Patients were strati-
fied based on AHM use during 28-day baseline and rando-
mized (1:1) to onabotulinumtoxinA (155-195U) or placebo
every 12 weeks. Multiple headache-symptom measures
were evaluated at Week 24, including mean change from
baseline in headache-day frequency (primary). Pooled
results from MO-No subgroup are reported.
Results
480 (n=243 onabotulinumtoxinA; n=237 placebo) of 1384
patients met MO-No criteria. At Week 24, onabotulinum-
toxinA treatment significantly reduced headache-day fre-
quency compared to placebo (-8.8/onabotulinumtoxinA;
-7.3/placebo: p=0.013). Significant improvements from
baseline (p¡Ü0.027) also favored onabotulinumtoxinA at
Week 24 for frequency of migraine-days, moderate/severe
headache-days, total cumulative hours of headache on
headache-days, and percent of patients with severe (¡Ý60)
headache impact test (HIT-6) scores. Improvements in
total HIT-6 and migraine-specific questionnaire scores all
significantly favored onabotulinumtoxinA over placebo at
Week 24 (p¡Ü0.032). Few patients in this subgroup discon-
tinued because of an adverse event (AE); AEs were consis-
tent with overall PREEMPT tolerability.
Conclusion/relevance
OnabotulinumtoxinA is effective and well-tolerated for
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